Cell therapies are among the most exciting advancements in oncology
Several CAR T-cell therapies have already been granted approval by the FDA and EMA, but the field is broadening. New therapies are tapping into stem cells, T-cell receptors (TCR), tumor-infiltrating lymphocytes, macrophages, and NK-cells to explore their therapeutic potential.
While these therapies can be more effective at targeting solid tumors, they face barriers throughout development.
- Complex manufacturing processes
- Rigorous regulatory expectations
- Shortages of qualified staff and laboratories
- Market access and commercialization challenges
Gain the insights needed to understand and overcome the unique clinical, translational, logistical, and manufacturing challenges associated with developing a novel cell therapy in this free ungated eBook.
Read first-hand insights from experts in oncology cell therapy
Within this resource, we go into detail on the current and future state of cell therapy development.
- Environment: Current trends, in-depth breakdowns, and unrealized opportunities
- Execution: Key nuances of cell therapy clinical trials, from therapeutic development, regulatory, and manufacturing considerations to site selection, lab partners, logistics, and data monitoring
- Evolution: Ways to streamline insight generation that drive efficiency and propel cell therapy clinical trial execution forward
